‘Quanticel’ the Company Later?
Pharmakea Inks Celgene Deal: $35M for Cancer and Fibrotic Push
By Randy Osborne
Friday, October 4, 2013
Celgene Corp. put still more chips on the biotech table, entering a confirmed $35 million deal to develop cancer and fibrotic-disease therapies with Pharmakea Therapeutics Inc., which at the same time pulled down $10 million in a Series A funding round from Bay City Capital.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.